A Phase 1, Randomized, Parallel Assignment, Double Blind, Placebo Controlled, Single and Multiple Ascending Dose, Safety, Tolerability, and Pharmacokinetic Study of ZT002 in Healthy Participants
Latest Information Update: 24 May 2024
At a glance
- Drugs ZT 002 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors QL Biopharmaceutical
Most Recent Events
- 24 May 2024 New trial record